Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SI HOUN HAHN

Allopathic & Osteopathic Physicians Medical Genetics Clinical Biochemical Genetics

NPI
1538109558
CMS profile
296702
Location
SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$321.22

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $321.22 3

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Alexion Pharmaceuticals, Inc. $276.22 2
GENZYME CORPORATION $45.00 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SI HOUN HAHN

NPI 1538109558 · CMS profile ID 296702

Allopathic & Osteopathic Physicians / Medical Genetics / Clinical Biochemical Genetics

SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538109558?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SI HOUN HAHN, NPI 1538109558, CMS profile ID 296702. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538109558?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SI HOUN HAHN, NPI 1538109558, CMS profile ID 296702. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538109558?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SI HOUN HAHN, NPI 1538109558, CMS profile ID 296702, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1538109558?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $321.22 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alexion Pharmaceuticals, Inc. $123.1211/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695611599 CMS
Alexion Pharmaceuticals, Inc. $153.1005/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695611603 CMS
GENZYME CORPORATION $45.0004/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694017123 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $321.22 3
PY2021 $30.00 1
PY2022 $10,125.00 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $69,020.68 15
PY2024 Principal investigator $233,637.44 34
PY2023 Principal investigator $187,673.30 23
PY2022 Recipient $1,000.00 2
PY2022 Principal investigator $161,500.08 16
PY2021 Recipient $2,750.00 5
PY2021 Principal investigator $207,039.98 16
PY2020 Recipient $2,358.70 4
PY2020 Principal investigator $216,984.24 11
PY2019 Recipient $1,564.27 4
PY2019 Principal investigator $276,900.00 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

34 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $11,650.00 12/03/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ402666) in Patients With Infantile-onset Pompe Disease Treated With Alglucosidase Alfa Who Demonstrate Clinical Decline or Sub-optimal Clinical Response No dispute reported 06/30/2026 1128720161
Principal investigator 1 GENZYME CORPORATION $1,250.00 11/12/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ402666) in Patients With Infantile-onset Pompe Disease Treated With Alglucosidase Alfa Who Demonstrate Clinical Decline or Sub-optimal Clinical Response No dispute reported 06/30/2026 1128720159
Principal investigator 1 GENZYME CORPORATION $1,875.00 09/16/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ402666) in Patients With Infantile-onset Pompe Disease Treated With Alglucosidase Alfa Who Demonstrate Clinical Decline or Sub-optimal Clinical Response No dispute reported 06/30/2026 1128720157
Principal investigator 1 GENZYME CORPORATION $3,975.00 08/19/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ402666) in Patients With Infantile-onset Pompe Disease Treated With Alglucosidase Alfa Who Demonstrate Clinical Decline or Sub-optimal Clinical Response No dispute reported 06/30/2026 1128720155
Principal investigator 1 Ultragenyx Pharmaceutical Inc. $4,298.70 08/14/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
UX701-CL301 No dispute reported 06/30/2026 1150280790
Principal investigator 1 GENZYME CORPORATION $519.00 07/22/2024 Non-covered Recipient Entity
Wcg Irb
An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ402666) in Patients With Infantile-onset Pompe Disease Treated With Alglucosidase Alfa Who Demonstrate Clinical Decline or Sub-optimal Clinical Response No dispute reported 06/30/2026 1128708575
Principal investigator 1 GENZYME CORPORATION $95.00 07/22/2024 Non-covered Recipient Entity
Wcg Irb
An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ402666) in Patients With Infantile-onset Pompe Disease Treated With Alglucosidase Alfa Who Demonstrate Clinical Decline or Sub-optimal Clinical Response No dispute reported 06/30/2026 1128708577
Principal investigator 1 Ultragenyx Pharmaceutical Inc. $5,511.80 07/17/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
UX701-CL301 No dispute reported 06/30/2026 1150280796
Principal investigator 1 Ultragenyx Pharmaceutical Inc. $6,190.00 07/10/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
UX701-CL301 No dispute reported 06/30/2026 1150280792
Principal investigator 1 Ultragenyx Pharmaceutical Inc. $7,525.46 07/10/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
UX701-CL301 No dispute reported 06/30/2026 1150280794
Principal investigator 1 GENZYME CORPORATION $3,763.00 06/04/2024 Non-covered Recipient Entity
Wcg Irb
An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ402666) in Patients With Infantile-onset Pompe Disease Treated With Alglucosidase Alfa Who Demonstrate Clinical Decline or Sub-optimal Clinical Response No dispute reported 06/30/2026 1128708567
Principal investigator 1 GENZYME CORPORATION $1,875.00 06/04/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ402666) in Patients With Infantile-onset Pompe Disease Treated With Alglucosidase Alfa Who Demonstrate Clinical Decline or Sub-optimal Clinical Response No dispute reported 06/30/2026 1128720149
Principal investigator 1 Alexion Pharmaceuticals, Inc. $41,285.70 05/16/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
A Phase 3, Randomized, Rater Blinded, Multi Center Study to Evaluate the Efficacy and Safety of ALXN1840 (WTX101) Administered for 48 Weeks versus Standard of Care in Patients with Wilson Disease Aged 12 Years and Older, with an Extension Period of up to 60 Months No dispute reported 06/30/2026 1110839162
Principal investigator 1 Ultragenyx Pharmaceutical Inc. $16,219.65 05/10/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
UX701-CL301 No dispute reported 06/30/2026 1150280778
Principal investigator 1 Ultragenyx Pharmaceutical Inc. $2,082.80 05/01/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
UX701-CL301 No dispute reported 06/30/2026 1150280784
Principal investigator 1 GENZYME CORPORATION $625.00 04/15/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ402666) in Patients With Infantile-onset Pompe Disease Treated With Alglucosidase Alfa Who Demonstrate Clinical Decline or Sub-optimal Clinical Response No dispute reported 06/30/2026 1128720153
Principal investigator 1 Ultragenyx Pharmaceutical Inc. $6,642.90 04/01/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
UX701-CL301 No dispute reported 06/30/2026 1150280780
Principal investigator 1 Ultragenyx Pharmaceutical Inc. $4,848.63 04/01/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
UX701-CL301 No dispute reported 06/30/2026 1150280782
Principal investigator 1 Ultragenyx Pharmaceutical Inc. $390.90 04/01/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
UX701-CL301 No dispute reported 06/30/2026 1150280786
Principal investigator 1 Ultragenyx Pharmaceutical Inc. $1,414.78 04/01/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
UX701-CL301 No dispute reported 06/30/2026 1150280788
Principal investigator 1 Alexion Pharmaceuticals, Inc. $67,345.00 03/21/2024 Non-covered Recipient Entity
SEATTLE CHILDRENS HOSPITAL RESEARCH AND FOUNDATION
A Phase 3, Randomized, Rater Blinded, Multi Center Study to Evaluate the Efficacy and Safety of ALXN1840 (WTX101) Administered for 48 Weeks versus Standard of Care in Patients with Wilson Disease Aged 12 Years and Older, with an Extension Period of up to 60 Months No dispute reported 06/30/2026 1110844722
Principal investigator 1 GENZYME CORPORATION $1,875.00 03/18/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ402666) in Patients With Infantile-onset Pompe Disease Treated With Alglucosidase Alfa Who Demonstrate Clinical Decline or Sub-optimal Clinical Response No dispute reported 06/30/2026 1128720145
Principal investigator 1 GENZYME CORPORATION $1,549.91 03/18/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
A Prospective Observational Study to Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients =6 Months of Age With Infantile-onset Pompe Disease (IOPD) No dispute reported 06/30/2026 1128720147
Principal investigator 1 GENZYME CORPORATION $3,700.00 03/11/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Avalglucosidase Alfa in Treatment naive Pediatric Participants With Infantile-Onset Pompe Disease (IOPD) No dispute reported 06/30/2026 1128720131
Principal investigator 1 GENZYME CORPORATION $1,154.00 03/04/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ402666) in Patients With Infantile-onset Pompe Disease Treated With Alglucosidase Alfa Who Demonstrate Clinical Decline or Sub-optimal Clinical Response No dispute reported 06/30/2026 1128720129
Principal investigator 1 Ultragenyx Pharmaceutical Inc. $19,122.39 02/28/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
UX701-CL301 No dispute reported 06/30/2026 1150280776
Principal investigator 1 GENZYME CORPORATION $1,875.00 02/12/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ402666) in Patients With Infantile-onset Pompe Disease Treated With Alglucosidase Alfa Who Demonstrate Clinical Decline or Sub-optimal Clinical Response No dispute reported 06/30/2026 1128720127
Principal investigator 1 Ultragenyx Pharmaceutical Inc. $5,219.70 01/19/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
UX701-CL301 No dispute reported 06/30/2026 1150280766
Principal investigator 1 Ultragenyx Pharmaceutical Inc. $3,495.78 01/19/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
UX701-CL301 No dispute reported 06/30/2026 1150280768
Principal investigator 1 Ultragenyx Pharmaceutical Inc. $1,295.40 01/19/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
UX701-CL301 No dispute reported 06/30/2026 1150280770
Principal investigator 1 Ultragenyx Pharmaceutical Inc. $910.63 01/19/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
UX701-CL301 No dispute reported 06/30/2026 1150280772
Principal investigator 1 Ultragenyx Pharmaceutical Inc. $312.19 01/19/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
UX701-CL301 No dispute reported 06/30/2026 1150280774
Principal investigator 1 GENZYME CORPORATION $625.00 01/16/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ402666) in Patients With Infantile-onset Pompe Disease Treated With Alglucosidase Alfa Who Demonstrate Clinical Decline or Sub-optimal Clinical Response No dispute reported 06/30/2026 1128720125
Principal investigator 1 Ultragenyx Pharmaceutical Inc. $3,119.12 01/03/2024 Covered Recipient Teaching Hospital
Seattle Childrens Hospital
UX701-CL301 No dispute reported 06/30/2026 1150280764